An antagonist to platelet activating factor counteracts the tumoricidal action of alkyl lysophospholipids.
Bazill
G W
GW
Paterson Institute for Cancer Research, Manchester, U.K.
Dexter
T M
TM
D001692:Biological Transport / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D005663:Furans / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D010742:Phospholipid Ethers / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface / Q000187:drug effects; D043562:Receptors, G-Protein-Coupled; D014407:Tumor Cells, Cultured
D005663:Furans; D010742:Phospholipid Ethers; D010972:Platelet Activating Factor; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; C039351:platelet activating factor receptor; C055462:SRI 62-834; C026659:edelfosine; C047504:2,5-bis(3,4,5-trimethoxyphenyl)tetrahydrofuran